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Intestinal injury that results from chemotherapy belongs to the major factors of dose-limitation in tumour therapy. The tyrphostins
AG1714 and AG1801 reduce cisplatin and 5-FU-induced small intestinal mucosal damage, using a quantitative biochemical assay. The
assay is based on the determination of the enzymatic activity of gamma-glutamyl transpeptidase, a marker of the brush border
epithelium of the small intestine.
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Intestinal mucositis is a common complication for a wide variety
of anticancer drugs (Khan and Wingard, 2001; Duncan and Grant,
2003).
Clinical trials demonstrated a chemoprotective effect of amifos-
tine (Phan et al, 2001), a granulocyte–macrophage colony
stimulating factor (Meropol et al, 1999) and glutamine (Daniele
et al, 2001) against chemotherapy-induced intestinal toxicity. We
have reported the protective effect of the tyrphostin AG1714
against chemotherapy-induced toxicity without impairing its
antitumour efficacy in mice (Novogrodsky et al, 1998). Epithelium
injury was assessed by histopathological analysis. Here, we present
data on the prevention by the tyrphostins AG1714 and AG1801 of
cisplatin and 5-fluorouracil (5-FU)-induced intestinal mucosal
damage, using a quantitative biochemical assay. The assay is based
on the determination of the enzymatic activity of gamma-glutamyl
transpeptidase (GGT), a marker of the brush border epithelium of
the small intestine (Tate and Meister, 1981; Ferraris et al, 1992).
MATERIALS AND METHODS
Mice
CD1 female mice (20–25g) were obtained from Harlan, Jerusalem.
The experimental protocol was approved by the Committee for
Care and Use of Laboratory Animals, Rabin Medical Center-
Beilinson Campus.
Materials
AG1714 and AG1801 were synthesised as described (Gazit et al,
1989). Cisplatin, (Sigma, Israel) was dissolved in DMSO (Burdick &
Jackson Division, Baxter Healthcare, Muskegon, MI, USA) to
obtain a solution of 50mgml
 1 and was diluted in saline to
1.0mgml
 1. 5-Fluorouracil (5-FU), 50mgml
 1, was obtained from
ABIC, Israel and diluted in saline. Doxorubicin, 2.0mgml
 1, was
obtained from TEVA, Israel, and diluted in PBS.
Formulations
For intraperitoneal (i.p.) injections, tyrphostins were dissolved in
cremophor (Sigma, Israel)–absolute ethanol (1:1w/w
 1) and
diluted in PBS (without calcium and magnesium). For oral
administration, tyrphostins were dissolved in polyethylene glycol
(PEG 400) (Sigma, Israel).
Treatment protocol
Tyrphostins’ solutions were freshly prepared immediately before
use. They were injected i.p. in a volume of 0.2–0.4ml 2h prior to
the cytotoxic agents, or administered orally in a volume 0.2ml, 4h
prior to the administration of the cytotoxic drugs. Control mice
were administered with vehicle solutions.
Gamma-glutamyl transpeptidase assay
Mice were killed by cervical dislocation.
A segment of the jejunum (approximately 5cm) was isolated, cut
and placed into a tube containing ice cold PBS (2.5ml). The
intestinal segments were then flushed with 10ml of PBS. In total,
2 2cm
2 segments were (for duplication) cut, and placed into
1.0ml of 1.0% Triton X-100, 0.15 M NaCl, 100mM Tris, pH 8.0
(Tris-Triton buffer) and stirred for 2min. After 30min in ice, the
tubes were centrifuged and the supernatants were diluted 1:1 with
Tris-Triton buffer. A measure of 0.02ml were added to a reaction
mixture containing: 0.3ml of 100mM glycyl-glycine, pH 8.0,
0.08ml Tris-Triton buffer, 0.5ml of 5mM gamma-glutamyl-p-
nitroanilide (dissolved in 100mM Tris, pH 8.0) (final volume,
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s0.9ml). All the reagents for GGT determination were obtained
from Sigma, Israel.
After incubation for 10min in a shaking water bath at 371C, the
reaction was stopped by placing the tubes in ice and adding 0.1ml
of glacial acetic acid. After centrifugation, supernatants were read
at 405nm (ELISA). Results were expressed as units of GGT activity
per cm of jejunum. One unit is defined as GGT activity, which
releases 1.0mmol of p-nitroaniline in 1h.
Statistical analysis
The results were expressed as means7s.e.m. Differences among
the treatment groups were evaluated using the two-tailed Student’s
t-test. P-values of o0.05 were considered statistically significant.
RESULTS
Figure 1 illustrates the chemical structure of AG1714 and AG1801.
As depicted in Figure 2, cisplatin (10mgkg
 1), injected
intraperitoneally (i.p.), markedly reduced the content of the GGT
in the small intestine jejunum mucosa of mice, as determined 4
days later. Administration of AG1714 (20mgkg
 1i.p.) 2h prior to
injection of cisplatin, abrogated the cisplatin effect by more than
two-fold. AG1801 is a structural analogue of AG1714 that shares
with it chemoprotective properties such as reduction of che-
motherapy-induced mortality and myelosuppression. AG1801 is
effective at a lower dose compared to AG1714. Maximal
chemoprotective effect of the tyrphostins, administered orally,
was attained at higher doses compared to i.p. administration
(unpublished observations).
AG1801 is also effective in attenuating chemotherapy-induced
small intestinal injury as assessed by determination of GGT
activity in the jejunum mucosa.
As depicted in Figure 3A, AG1801 (0.5–1.0mgkg
 1), adminis-
tered intraperitoneally 2h prior to cisplatin, abrogated the
cisplatin (10mgkg
 1, i.p.) effect by almost two-fold. Oral
administration of AG1801 (50mgkg
 1), 4h prior to cisplatin,
almost completely prevented cisplatin (10mgkg
 1, i.p.)-induced
small intestinal injury (Figure 3B).
AG1801, administered orally was also effective in reducing 5-FU-
induced small intestinal injury. Oral administration of AG1801, 4h
prior to 5-FU, markedly reduced 5-FU (200mgkg
 1, i.p.)-induced
small intestinal injury (Figure 4).
DISCUSSION
Using the quantitative biochemical GGT method, we demonstrated
the protective effect of the tyrphostins AG1714 and AG1801 against
chemotherapy-induced small intestinal injury. We have previously
demonstrated the protective effect of AG1714 against cisplatin
induced small intestinal toxicity, using histological analysis
(Novogrodsky et al, 1998). The biochemical method supplements
histological analysis, and has the advantage of providing an
objective quantitative assessment of the integrity of the mucosa in
a large segment of the intestine.
Oral administration of the tyrphostins seems to be more
effective than the intraperitoneal route. This may be due to the
direct access of the tyrphostins to the intestinal mucosa.
Chemotherapeutic agents induce intestinal toxicity by an
apoptosis-mediated mechanism (Potten et al, 1997; Papaconstan-
tinou et al, 2001).
We have previously (Novogrodsky et al, 1998; Vanichkin et al,
2002) postulated that the chemoprotective effect of the tyrphostins
is attributed to their ability to selectively inhibit the induction of
apoptosis in normal cells but not in cancer cells.
The molecular targets of AG1714 and AG1801 are unknown.
These compounds are structurally related to the tyrphostin family
that selectively inhibits protein tyrosine kinases (Levitzki and
Gazit, 1995). Inhibitors of tyrosine kinases were shown to
modulate apoptosis induced by a variety of agents in different
cell types (Uckun et al, 1992; Bergamaschi et al, 1993; Liu et al,
1994; Ji et al, 1995). It should be noted, however, that AG1714 and
AG1801 are not derivatives of hydroxylbenzylidene malononitrile
like most of the reported tyrosine kinase inhibitors of the
tyrphostin family. Thus, it is not at all certain that the effect of
AG1714 and AG1801 reported here is related to the inhibition of
protein tyrosine kinases(s). Moreover, as noted above, these
compounds are effective upon administration 2–4h prior to
chemotherapy. The i.p. (10mgkg
 1) bioavailability of AG1801 was
calculated to be about 26% and the oral (20mgkg
 1) bioavail-
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Figure 1 Structure of AG1714 and AG1801.
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Figure 2 Effect of AG1714 (i.p.) on cisplatin-induced reduction of
intestinal GGT. CD1 mice were injected (i.p.) with AG1714, 2h prior to
injection (i.p.) of cisplatin. Mice were killed 4 days after cisplatin
administration and small intestinal GGT was determined as described in
Materials and Methods. The number of mice (n) in each experimental
group is depicted in the figure. Figure includes data from five different
experiments. Results are expressed as units of GGT activity per 1cm of
small intestinal jejunum7s.e.m. ***Po0.001, mice treated with cispla-
tinþAG1714 vs cisplatin alone.
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sability was calculated to be 21%. However, AG1801 is cleared
rapidly from the blood (T1/2, is less than 10min). Hence, at the
time of the administration of chemotherapy, the blood level of
AG1801 may be very low. AG1801 may elicit its effect by providing
a signal, rendering the cell resistant to the induction of apoptotic
injury. It is also possible that a degradation product of AG1801
rather than the native compound elicits the biological effect.
The study reported here was confined to biochemical monitor-
ing of acute small intestinal injury in the mouse induced by
chemotherapy. The GGT method is not suitable for assessment of
large intestinal damage due to the low content of GGT. The
applicability of this method to other species or other types of
intestinal damage, such as those associated with inflammatory
processes, requires further investigation. In this context, it should
be noted that GGT in different cell types is subject to phenotypic
alterations induced by different agents (Novogrodsky et al, 1976;
Wasserman et al, 1987; Sidi et al, 1988).
It is very difficult to quantitatively assess the sensitivity of
biochemical GGT assay in comparison to the histological assay.
However, The intestinal injury induced by chemotherapy is quite
often nonhomogenous and therefore the biochemical assay that
analyses a long segment of the intestine (centimeters) is superior
to the histological assay that analyses a very small segment
(microns).
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Figure 4 Effect of AG1801 (administered orally) on 5-FU-induced
reduction of intestinal GGT. Mice were injected (i.p.) with 5-FU
(200mgkg
 1) 4h after oral administration of AG1801 (50mgkg
 1).
Intestinal GGT was determined 4 days after cisplatin administration. Figure
includes data from three different experiments. ***Po0.001, mice treated
with 5-FUþAG1801 vs 5-FU alone.
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